Ad
related to: epipen epinephrine costgoodrx.com has been visited by 100K+ users in the past month
"A prescription drug card that actually does work" - BBB.org
Search results
Results from the WOW.Com Content Network
People with the condition are often prescribed a specific type of medication for life-threatening reactions -- but its cost has risen by over 480 percent. EpiPens are now so expensive that some ...
An epinephrine autoinjector (or adrenaline autoinjector, also known by the trademark EpiPen) is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
The EpiPen, and its maker Mylan Pharmaceuticals, have been all over the news as of late. But price hikes on crucial medicine go far beyond the Epi-Pen. EpiPen isn't the only emergency medicine ...
There is an epinephrine metered-dose inhaler sold over the counter in the United States to relieve bronchial asthma. [67] [68] It was introduced in 1963 by Armstrong Pharmaceuticals. [69] A common concentration for epinephrine is 2.25% w/v epinephrine in solution, which contains 22.5 mg/mL, while a 1% solution is typically used for aerosolization.
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
The first-ever needle-free alternative to the EpiPen and similar epinephrine autoinjectors has been approved by the Food and Drug Administration to treat anaphylaxis.. Neffy, a nasal spray that ...
The "Auvi-Q" epinephrine autoinjector uses this design. [ 8 ] A newer variant of the autoinjector is the gas jet autoinjector , which contains a cylinder of pressurized gas and propels a fine jet of liquid through the skin without using a needle.
Jul. 17—MORGANTOWN — Pfizer and two of its subsidiaries have agreed to a $345 million settlement in a four-year class-action antitrust lawsuit concerning Mylan's EpiPen.